
Coya Therapeutics Reports Positive Interim Results of IL-2 and CTLA4-Ig Combination in Mild to Moderate Frontotemporal Dementia
Coya Therapeutics Reports Positive Interim Results of IL-2 and CTLA4-Ig Combination in Mild to Moderate Frontotemporal Dementia Coya Therapeutics, Inc. , a clinical-stage biotechnology company specializing in the development of biologic therapies designed to enhance the function of regulatory T…